Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694538 | 0.91 | GSK3A (0.48) | GSK3AGSK3BCCR6 | |
| Acetic Acid SCHEMBL28849017 | 0.90 | GSK3A (0.42) | GSK3AGSK3BCCR6 | |
| Benzoic Acid SCHEMBL27698997 | 0.82 | DAO (0.45) | GSK3AGSK3BCCR6KDM4EPOLB | |
| SCHEMBL6270994 | 0.82 | — | — | |
| SCHEMBL1123 | 0.79 | — | — | |
| SCHEMBL338264 | 0.79 | KDM4E (0.34) | KDM4EGAAPOLB | |
| SCHEMBL785147 | 0.79 | — | — | |
| SCHEMBL8665043 | 0.76 | GSK3A (0.52) | GSK3AGSK3BCCR6 | |
| SCHEMBL23174460 | 0.76 | — | — | |
| SCHEMBL21409686 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262185-B1 | DNA DISPLAY AND METHODS THEREOF | UNIV HONG KONG (CN) | 2020-08-26 | — | — | EP | claimed |
| EP-3262185-A1 | DNA DISPLAY AND METHODS THEREOF | The University of Hong Kong (CN) | 2018-01-03 | — | — | EP | claimed |
| WO-2016134521-A1 | DNA DISPLAY AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2016-09-01 | — | — | WO | claimed |
| EP-0810876-B1 | INFLUENZA VIRUS SUBUNIT CONJUGATES | AVENTIS PASTEUR INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-20240197846-A1 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240189403-A1 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| US-12006348-B2 | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof | CUE BIOPHARMA, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240175034-A1 | FN3 DOMAIN-SIRNA CONJUGATES AND USES THEREOF | Aro Biotherapeutics Company (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024086713-A1 | FN3 DOMAIN-SIRNA CONJUGATES AND USES THEREOF | Aro Biotherapeutics Company (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4350330-A1 | NANOPARTICLE BODY, METHOD FOR PRODUCING SAME, AND NANOPARTICLE BODY COMPOSITION CONTAINING NANOPARTICLE BODY | PHC Holdings Corporation (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240082411-A1 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240043844-A1 | FN3 Domain-siRNA Conjugates with Enzyme Replacement Therapy | Aro Biotherapeutics Company | 2024-02-08 | — | — | US | disclosed |
| US-20080176769-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080050747-A1 | Articles having localized molecules disposed thereon and methods of producing and using same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080032301-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| EP-1540341-A4 | METHOD FOR DETERMINATION OF LIKELIHOOD OF OCCURRENCE OF PRETERM LABOR IN PREGNANT FEMALES | UNIV ROCHESTER MEDICAL CT (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060166295-A1 | Method for determination of likelihood of occurrence of preterm labor in pregnant females | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-07-27 | — | — | US | disclosed |
| EP-1540341-A1 | METHOD FOR DETERMINATION OF LIKELIHOOD OF OCCURRENCE OF PRETERM LABOR IN PREGNANT FEMALES | The University of Rochester Medical Center (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004003555-A1 | METHOD FOR DETERMINATION OF LIKELIHOOD OF OCCURRENCE OF PRETERM LABOR IN PREGNANT FEMALES | UNIVERSITY OF ROCHESTER MEDICAL CENTER (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-1991004273-A2 | NOVEL PEPTIDES ASSOCIATED WITH THE CD4 BINDING REGION OF GP120 AND THEIR METHODS OF USE | IDEC PHARMACEUTICALS CORP. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006348-B2 | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof | IL2, CD4, HLA-DRB1 | GSK3A 3211/4885GSK3B 2660/4885CCR6 208/4885 |
| US-20240175034-A1 | FN3 DOMAIN-SIRNA CONJUGATES AND USES THEREOF | FN1, ITGB3, FNIP1 | GSK3A 2898/4885GSK3B 3002/4885CCR6 1383/4885 |
| US-20240043844-A1 | FN3 Domain-siRNA Conjugates with Enzyme Replacement Therapy | FN1, TIMP3, DNASE1L3 | GSK3A 2138/4885GSK3B 2294/4885CCR6 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.